Kanghong Pharmaceutical released its 2026 half-year report, showing first-half net profit attributable to the parent of 565 million yuan, down 22.6% year on year. Operating revenue was 2.18 billion yuan, down 11.2% year on year. Net profit attributable to the parent after deducting non-recurring items was 557 million yuan, down 22.9% year on year. Net operating cash flow was 540 million yuan, down 41.1% year on year. Second-quarter operating revenue was 1.13 billion yuan, down 9.7% year on year, and net profit attributable to the parent was 257 million yuan, down 22.0% year on year. As of the end of the second quarter, total assets were 9.939 billion yuan, up 0.2% from the end of the previous year, and net assets attributable to the parent were 9.215 billion yuan, down 0.9% from the end of the previous year.
Chengdu Kanghong Pharmaceuticals Group Co LtdFirst-half net profit attributable to parent fell 22.6% to 565 million yuan, with revenue down 11.2%.
